ALT — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

20.51

Margin Of Safety %

Put/Call OI Ratio

0.1

EPS Next Q Diff

0.01

EPS Last/This Y

-0.17

EPS This/Next Y

-0.19

Price

3.39

Target Price

19.89

Analyst Recom

1.64

Performance Q

-17.36

Upside

-492.3%

Beta

0.35

Ticker: ALT

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	ALT	3.88	0.13	0.03	141689
2026-03-10	ALT	3.86	0.13	0.25	149092
2026-03-11	ALT	3.81	0.13	0.40	149794
2026-03-12	ALT	3.61	0.13	0.25	150809
2026-03-13	ALT	3.6	0.13	0.36	150809
2026-03-17	ALT	3.53	0.12	0.36	148030
2026-03-18	ALT	3.41	0.13	0.60	149973
2026-03-19	ALT	3.41	0.13	0.12	150247
2026-03-20	ALT	3.36	0.13	0.33	152208
2026-03-23	ALT	3.43	0.15	0.40	102418
2026-03-24	ALT	3.23	0.16	0.13	106284
2026-03-25	ALT	3.32	0.15	0.05	108434
2026-03-26	ALT	3.2	0.15	0.04	108861
2026-03-27	ALT	3.02	0.15	0.13	111666
2026-03-30	ALT	2.88	0.13	0.05	107709
2026-03-31	ALT	3.07	0.12	0.02	107803
2026-04-01	ALT	3.11	0.11	0.03	113690
2026-04-02	ALT	3.33	0.11	0.06	115065
2026-04-06	ALT	3.33	0.10	0.04	114802
2026-04-07	ALT	3.38	0.10	0.06	118524
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	ALT	3.88	-11.5	-216.1	-1.36
2026-03-10	ALT	3.86	-11.5	-143.4	-1.19
2026-03-11	ALT	3.81	-11.5	-138.0	-1.19
2026-03-12	ALT	3.61	-11.5	-113.9	-1.19
2026-03-13	ALT	3.51	1.7	-102.3	-1.19
2026-03-17	ALT	3.54	1.7	-106.1	-1.19
2026-03-18	ALT	3.41	1.7	-91.1	-1.19
2026-03-19	ALT	3.41	1.7	-91.5	-1.19
2026-03-20	ALT	3.36	3.9	-85.0	-1.17
2026-03-23	ALT	3.43	3.9	-109.7	-1.17
2026-03-24	ALT	3.23	3.9	-84.0	-1.17
2026-03-25	ALT	3.32	3.9	-95.5	-1.17
2026-03-26	ALT	3.21	3.9	-81.8	-1.17
2026-03-27	ALT	3.03	3.9	-59.8	-1.17
2026-03-30	ALT	2.87	3.9	-40.0	-1.17
2026-03-31	ALT	3.07	3.9	-64.6	-1.17
2026-04-01	ALT	3.12	3.9	-70.1	-1.17
2026-04-02	ALT	3.34	3.9	-97.9	-1.17
2026-04-06	ALT	3.33	3.9	-96.5	-1.17
2026-04-07	ALT	3.39	3.9	-105.0	-1.17
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	ALT	6.63	13.59	20.21
2026-03-10	ALT	6.63	13.59	20.21
2026-03-11	ALT	6.36	13.59	19.75
2026-03-12	ALT	6.36	13.59	19.75
2026-03-13	ALT	6.36	13.59	19.75
2026-03-17	ALT	6.36	11.65	19.75
2026-03-18	ALT	6.36	11.65	19.75
2026-03-19	ALT	6.36	11.65	19.75
2026-03-20	ALT	6.36	11.65	19.75
2026-03-23	ALT	6.36	11.70	19.75
2026-03-24	ALT	6.36	11.70	19.75
2026-03-25	ALT	6.36	11.70	20.51
2026-03-26	ALT	6.36	11.70	20.51
2026-03-27	ALT	6.36	11.70	20.51
2026-03-30	ALT	6.36	11.71	20.51
2026-03-31	ALT	6.36	11.71	20.51
2026-04-01	ALT	9.47	11.71	20.51
2026-04-02	ALT	9.47	11.71	20.51
2026-04-06	ALT	10.66	11.71	20.51
2026-04-07	ALT	10.66	11.71	20.51
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.27

Avg. EPS Est. Current Quarter

-0.25

Avg. EPS Est. Next Quarter

-0.26

Insider Transactions

10.66

Institutional Transactions

11.71

Beta

0.35

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.6

Max Drawdown 5-Year %

-90.5

Target Price

19.89

P/E

Forward P/E

PEG

P/S

10990.84

P/B

1.67

P/Free Cash Flow

EPS

-1.02

Average EPS Est. Cur. Y

-1.17

EPS Next Y. (Est.)

-1.36

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-214860.98

Relative Volume

0.5

Return on Equity vs Sector %

-66.6

Return on Equity vs Industry %

-50.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.08

EBIT Estimation

-105

◆ ALT Healthcare

$3.38

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

15/25

Volume

11/15

Valuation

12/20

TP/AR

3/10

Options

8/10

RSI

44.7

Range 1M

43.2%

Sup Dist

3.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

9/30

Estimates

2/20

Inst/Vol

5/15

Options

8/10

EPS Yr

-10%

EPS NY

-7.2%

52W%

10.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +488.5% upside

Quality

2/30

Valuation

16/30

Growth

6/25

Stability

7/10

LT Trend

1/5

Upside

+488.5%

Quality

Altimmune, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 57

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

ALT

Latest News

—

Caricamento notizie per ALT…

stock quote shares ALT – Altimmune, Inc. Stock Price stock today

news today ALT – Altimmune, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ALT – Altimmune, Inc. yahoo finance google finance

stock history ALT – Altimmune, Inc. invest stock market

stock prices ALT premarket after hours

ticker ALT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ALT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y